BiotechTube

ORMD-0801

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

T2DM (Type 2 Diabetes Mellitus)

Conditions

T2DM (Type 2 Diabetes Mellitus)

Trial Timeline

Mar 16, 2021 → Jan 13, 2023

NCT ID
NCT04754334

About ORMD-0801

ORMD-0801 is a phase 3 stage product being developed by Oramed Pharmaceuticals for T2DM (Type 2 Diabetes Mellitus). The current trial status is terminated. This product is registered under clinical trial identifier NCT04754334. Target conditions include T2DM (Type 2 Diabetes Mellitus).

What happened to similar drugs?

4 of 9 similar drugs in T2DM (Type 2 Diabetes Mellitus) were approved

Approved (4) Terminated (0) Active (5)
🔄Metformin + Alogliptin + empagliflozinCelltrionPhase 3
🔄CT-L03 Group 1 + CT-L03 Group 2 + Placebo + Empagliflozin + MetforminCelltrionPhase 3
✅Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets + Dapagliflozin tablets and Metformin HCl extended-release tabletsAstraZenecaApproved
✅Sitagliptin phosphate + Comparator: Sulfonylurea + MetforminMerckApproved
🔄sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day + comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/dayMerckPhase 3
✅Vildagliptin (LAF237) + Placebo + Insulin + MetforminNovartisApproved
🔄Vildagliptin + Metformin + sulfonylurea (SU) + Basal InsulinNovartisPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT04817215Phase 3UNKNOWN
NCT04754334Phase 3Terminated
NCT04564846Phase 2Completed

Competing Products

20 competing products in T2DM (Type 2 Diabetes Mellitus)

See all competitors
ProductCompanyStageHype Score
MKP10241 + PlaceboMankind PharmaPhase 2
42
Metformin + Alogliptin + empagliflozinCelltrionPhase 3
47
CT-L03 Group 1 + CT-L03 Group 2 + Placebo + Empagliflozin + MetforminCelltrionPhase 3
44
L03RD1 + L03RD2 + CT-L03CelltrionPhase 1
29
DulaglutideEli LillyPhase 1
36
SHR-3167 + SHR-3167 PlaceboJiangsu Hengrui MedicinePhase 1
25
AZD4076 + PlaceboAstraZenecaPhase 1
29
Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets + Dapagliflozin tablets and Metformin HCl extended-release tabletsAstraZenecaApproved
43
Dapagliflozin + Metformin XR + GlucophageAstraZenecaPhase 1
29
AZD8601+Placebo (SAD) + AZD8601+Placebo + Placebo+PlaceboAstraZenecaPhase 1
29
Saxagliptin 5 mg + Metformin XR 500 mg + Mertformin XR 2 x 500 mg + Komboglyze XR 5/500 mg + Komboglyze XR 5/1000 mgAstraZenecaPhase 1
29
Comparator: sitagliptin phosphate + Comparator: placebo (unspecified)MerckPhase 1
29
ErtugliflozinMerckPhase 1
29
Comparator: sitagliptin phosphate + Comparator: pioglitazone + Comparator: placebo to pioglitazone + Comparator: placebo to sitagliptinMerckPhase 1
29
Sitagliptin phosphate + Comparator: Sulfonylurea + MetforminMerckApproved
43
sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day + comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/dayMerckPhase 3
40
Vildagliptin (LAF237) + Placebo + Insulin + MetforminNovartisApproved
43
LIK066 + PlaceboNovartisPhase 1/2
32
Vildagliptin + Metformin + sulfonylurea (SU) + Basal InsulinNovartisPhase 3
40
Maridebart cafraglutide + PlaceboAmgenPhase 3
44